Table 1.
Baseline demographic and clinical characteristics of high-risk patients who received sotrovimab or remdesivir for mild to moderate coronavirus disease 2019.
| Total (N = 3257) | Remdesivir (N = 1099) | Sotrovimab (N = 2158) | p value | |
|---|---|---|---|---|
| Age (years), Median (IQR) | 64 (49, 73) | 69 (60, 76) | 60 (41, 71) | < 0.001 |
| Female | 1862 (57.2%) | 567 (51.6%) | 1295 (60.0%) | < 0.001 |
| Race | 0.006 | |||
| White | 3029 (93.0%) | 1037 (94.4%) | 1992 (92.3%) | |
| American Indian/Alaskan Native | 18 (0.6%) | 8 (0.7%) | 10 (0.5%) | |
| Asian | 47 (1.4%) | 12 (1.1%) | 35 (1.6%) | |
| Black or African American | 99 (3.0%) | 20 (1.8%) | 79 (3.7%) | |
| More than one race | 18 (0.6%) | 6 (0.5%) | 12 (0.6%) | |
| Native Hawaii/Pacific Islander | 4 (0.1%) | 0 (0.0%) | 4 (0.2%) | |
| Other | 21 (0.6%) | 4 (0.4%) | 17 (0.8%) | |
| Unknown | 21 (0.6%) | 12 (1.1%) | 9 (0.4%) | |
| Ethnicity | 0.73 | |||
| Hispanic or Latino | 135 (4.1%) | 44 (4.0%) | 91 (4.2%) | |
| Not Hispanic or Latino | 3084 (94.7%) | 1040 (94.6%) | 2044 (94.7%) | |
| Unknown | 38 (1.2%) | 15 (1.4%) | 23 (1.1%) | |
| Mean BMI (SD)a | 31.3 (7.3) | 32.3 (7.8) | 30.7 (7.0) | < 0.001 |
| Median serum creatinine (IQR)b | 1.0 (0.8, 1.2) | 1.0 (0.8, 1.2) | 1.0 (0.8, 1.2) | 0.27 |
| Median eGFR (IQR)b | 77.0 (60.3, 93.4) | 75.1 (59.2, 91.1) | 78.5 (60.8, 95.1) | < 0.001 |
| Received tixagevimab/cilgavimab | 7 (0.2%) | 1 (0.1%) | 6 (0.3%) | 0.28 |
| Number of COVID vaccines prior to start, Median (IQR) | 3 (2, 3) | 3 (2, 3) | 3 (2, 3) | 0.012 |
| 0 | 368 (11.3%) | 109 (9.9%) | 259 (12.0%) | |
| 1 | 94 (2.9%) | 18 (1.6%) | 76 (3.5%) | |
| 2 + | 2795 (85.8%) | 972 (88.4%) | 1823 (84.5%) | |
| Days from last vaccination to the initiation of drug therapy, Median (IQR) | 129 (95, 163) | 116 (90, 150) | 137 (98, 168) | < 0.001 |
| Charlson Comorbidity Index, Median (IQR) | 3 (1, 6) | 4 (2, 7) | 3 (1, 6) | < 0.001 |
| MASS Score, Median (IQR) | 5 (4, 7) | 6 (4, 8) | 5 (3, 7) | < 0.001 |
| MASS components | ||||
| Age ≥ 65 | 1626 (49.9%) | 740 (67.3%) | 886 (41.1%) | < 0.001 |
| BMI ≥ 35 | 1090 (33.5%) | 436 (39.7%) | 654 (30.3%) | < 0.001 |
| Cardiovascular disease | 1057 (32.5%) | 519 (47.2%) | 538 (24.9%) | < 0.001 |
| Chronic respiratory disease | 635 (19.5%) | 335 (30.5%) | 300 (13.9%) | < 0.001 |
| Chronic kidney disease stage IV/V | 183 (5.6%) | 64 (5.8%) | 119 (5.5%) | 0.72 |
| Diabetes mellitus | 888 (27.3%) | 425 (38.7%) | 463 (21.5%) | < 0.001 |
| Hypertension | 1577 (48.4%) | 732 (66.6%) | 845 (39.2%) | < 0.001 |
| Immunocompromised status | 1353 (41.6%) | 332 (30.2%) | 1021 (47.3%) | < 0.001 |
| Pregnancy | 306 (9.4%) | 0 (0.0%) | 306 (14.2%) | < 0.001 |
This table demonstrated baseline demographic of this population. Patients treated with sotrovimab were younger and had lower comorbidity but were more likely to be immunocompromised than remdesivir-treated patients.
aAvailable in 2704 (933 remdesivir and 1771 sotrovimab).
bAvailable in 2686 (974 remdesivir and 1712 sotrovimab).